ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
DISCOVERY
From novel biology to clinical stage products.
Rich Pipeline
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Experienced team
Our team brings success from biotech pharma, and academia to OncoC4.
ONC-781, 782, 783, and 784
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
Exploring Our Pipeline:
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Rising To The Most Pressing Challenge In Immunotherapy
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
YANG LIU, PHD
CHIEF EXECUTIVE OFFICER & CHIEF SCIENTIFIC OFFICER
Latest News
OncoC4 Strengthens Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer
ROCKVILLE, Md., USA, Sept 28, 2023 (GLOBE NEWSWIRE) — OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately. Abid brings over 20 years of expertise in financial strategy and business development for public and…
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications The randomized Phase 3 trial is expected to enroll approximately 600 patients with…
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual…